Skip to main content
Selvita S.A. logo

Selvita S.A. — Investor Relations & Filings

Ticker · SLV ISIN · PLSLVCR00029 LEI · 25940057WQ9YP5MOQF28 WAR Professional, scientific and technical activities
Open in API
Filings indexed 1,179 across all filing types
Latest filing 2024-03-28 Annual Report
Country PL Poland
Listing WAR SLV

About Selvita S.A.

https://selvita.com/

Selvita S.A. is a preclinical contract research organization (CRO) providing integrated services for the pharmaceutical and biotechnology sectors. The company offers comprehensive solutions across the drug discovery and development continuum, from target validation to preclinical candidate nomination. Core drug discovery capabilities include medicinal chemistry, pharmacology, DMPK, and protein sciences, supporting a wide range of modalities such as small molecules, antibodies, and protein degraders. For drug development, Selvita provides analytical support for small and large molecules, formulation, microbiology services, and manufacturing for clinical trials. The company operates under GMP and GLP quality standards, offering flexible engagement models that range from standalone studies to fully integrated programs.

Recent filings

Filing Released Lang Actions
SPRAWOZDANIE ZARZĄDU SELVITA SA z działalności Grupy Kapitałowej 2023
Annual Report Classification · 100% confidence The document is titled 'Sprawozdanie Zarządu Selvita S.A. z działalności Grupy Kapitałowej za rok obrotowy 2023' (Management Board Report of Selvita S.A. on the activities of the Selvita Capital Group for the 2023 financial year). It contains comprehensive financial statements, management commentary, governance information, and risk factors for the full fiscal year. As it covers the full annual period and includes audited financial data, it is classified as an Annual Report (10-K). FY 2023
2024-03-28 Polish
SELVITA CAPITAL GROUP ANNUAL REPORT 2023
Annual Report Classification · 100% confidence The document is titled 'Selvita Capital Group Annual Report 2023'. It contains comprehensive financial statements, management commentary, corporate governance disclosures, and audit information for the full fiscal year 2023. It is clearly a full annual report rather than an announcement or a summary. FY 2023
2024-03-28 English
Ocena Rady Nadzorczej Selvita S.A. dotycząca sprawozdań Zarządu z działalności oraz sprawozdań finansowych Selvita S.A. i Grupy Kapitałowej Selvita za rok 2023
Board/Management Information Classification · 99% confidence The document is titled 'Ocena Rady Nadzorczej Selvita S.A. dotycząca sprawozdań Zarządu z działalności oraz sprawozdań finansowych Selvita S.A. i Grupy Kapitałowej Selvita za rok 2023' (Statement of the Supervisory Board of Selvita S.A. regarding the Management Board's reports on the operations and financial statements... for 2023). This document explicitly details the Supervisory Board's assessment and approval of the annual financial statements and management reports for the year 2023, referencing Polish regulatory requirements for periodic information disclosure. While it discusses the Annual Report (10-K equivalent), the document itself is the formal opinion/assessment provided by the Supervisory Board on those reports, often filed alongside them or as a required governance disclosure. This fits best under Governance Information (CGR) as it relates to internal rules, board structure, and oversight practices regarding financial reporting, or potentially Audit Report/Information (AR) due to the review of financial statements and auditor reports. Given the focus on the Supervisory Board's formal review and statement on the *management's* reports and financial statements, CGR (Governance Information) is a strong fit, as it pertains to the board's oversight function. However, since it directly evaluates the annual financial statements and management reports, and often these assessments are filed as part of the overall annual audit/governance package, AR (Audit Report / Information) is also plausible if it's treated as the formal sign-off on the audit process results. Since the primary content is the Supervisory Board's formal opinion on the *financial statements* and *management reports* after reviewing the auditor's report, it aligns closely with the scope of an Audit Report/Information (AR) or Governance (CGR). Given the context of reviewing the full year's financial statements and the auditor's report, AR is slightly more specific than general governance disclosures.
2024-03-28 Polish
Oświadczenie Rady Nadzorczej Selvita S.A. dotyczące funkcjonowania Komitetu Audytu oraz firmy audytorskiej w Selvita S.A. oraz Grupie Kapitałowej Selvita
Audit Report / Information Classification · 99% confidence The document is a formal statement from the Supervisory Board of Selvita S.A. regarding the functioning of the Audit Committee and the external auditor (Pricewaterhousecoopers). It explicitly references the preparation and publication of the 'standalone and consolidated annual report for year 2023' and confirms compliance with regulations concerning the audit process, independence, and rotation. This type of declaration, focusing specifically on the audit function and compliance related to the annual financial statements, aligns best with the 'Audit Report / Information' category, which covers standalone audit reports and applied accounting principles, distinguishing it from the full Annual Report (10-K) or a general Governance Report (CGR). Given the focus on the auditor's compliance and the audit committee's role in relation to the annual report, AR is the most appropriate classification. FY 2023
2024-03-28 Polish
List Prezesa Selvita SA do Akcjonariuszy
Audit Report / Information Classification · 95% confidence The document is a formal address to shareholders and partners, summarizing the company's (Selvita S.A.) performance, strategic achievements (like completing the Hexagon lab building), challenges faced (CRO industry headwinds, biotech funding), and outlook for the coming year (2024). It discusses financial performance ('pod względem finansowym nie był tak dobry'), operational areas (drug discovery, drug development), and thanks employees and investors. This content structure strongly suggests a high-level review of the past fiscal year, which is characteristic of an Annual Report (10-K) or a summary/letter accompanying it. Since the text is a narrative letter from the CEO summarizing the entire year's activities and results, it aligns best with the content typically found in the Management Discussion and Analysis (MDA) section of a comprehensive annual filing, or a formal Annual Report itself. Given the depth of the review covering strategy, operations, and financial context for the full year 2023, classifying it as a Management Report (MDA) is appropriate, as it is a detailed explanation of results and trends by management, distinct from the formal 10-K filing itself, but often included within or accompanying it. However, since the text reads like a formal letter summarizing the entire year's performance and outlook, it is highly representative of the narrative component of an Annual Report (10-K) or a detailed Management Discussion and Analysis (MDA). Given the options, MDA captures the essence of management's detailed explanation of results and trends better than the general 10-K if this is an excerpt or standalone management commentary, but the tone and scope are very broad, often seen in the Chairman's/CEO's letter within the 10-K or Annual Report (AR). Since it is a comprehensive review of the full year's performance and strategy, and not just a short earnings release (ER) or a standalone audit report (AR), and it is not a presentation (IP) or a call transcript (CT), MDA is the most fitting category for this detailed management commentary on the year's results and outlook. FY 2023
2024-03-28 Polish
Sprawozdanie niezależnego biegłego rewidenta z badania (grupa kapitałowa) xades
Regulatory Filings Classification · 95% confidence The provided document text consists almost entirely of XML structures related to digital signatures (Signature, SignedInfo, KeyInfo, X509Data, etc.). Specifically, it contains references to 'GK_Selvita_SBR_2023_.xhtml' and various certificate details from Polish entities (Certum, Narodowy Bank Polski). This structure strongly indicates a digitally signed document, likely a regulatory filing or report that has been authenticated using an electronic signature standard (like XAdES, suggested by the namespaces). Since the content is the signature block itself and not the narrative or financial data of a report, and given the presence of a specific file name ('GK_Selvita_SBR_2023_.xhtml') being referenced, this is most likely the metadata or wrapper around a primary filing. Without the actual content of the referenced file, the most appropriate classification for a document that is fundamentally a signed regulatory artifact, especially one referencing a specific report name, is the general 'Regulatory Filings' fallback category (RNS), as it is not clearly an announcement (RPA) but the signed container itself, or potentially a specific report type if 'SBR' could be mapped, but RNS is safer for generic signed artifacts.
2024-03-28 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.